Skip to main content
. 2011 Oct 1;184(7):842–847. doi: 10.1164/rccm.201104-0668OC

TABLE 1.

PARTICIPANT CHARACTERISTICS

Quartile of Delay
No. <1 yr 1–2 yr 2–4 yr 4 yr
No. 33 32 33 31
Age, yr 129 64 (6) 62 (10) 62 (8) 65 (6)
Male 129 69% 66% 91% 77%
Race/ethnicity
 Non-Hispanic white 88% 78% 81% 90%
 Non-Hispanic black 3% 3% 9% 3%
 Hispanic (any race) 6% 9% 9% 3%
 Other 3% 9% 0% 3%
Body mass index, kg/m2 129 30 (6) 27 (4) 28 (6) 28 (4)
Former or current smoker* 128 48% 66% 73% 63%
Cigarette pack-years* 128 18 (13–41) 18 (5–38) 17 (6–24) 24 (14–47)
FVC, % predicted 129 54 (21) 50 (21) 54 (18) 54 (23)
DlCO, % predicted 123 41 (9) 38 (14) 41 (17) 38 (11)
NYHA class 129
 I–II 64% 47% 52% 45%
 III–IV 36% 53% 48% 55%
Months from evaluation to enrollment 129 4 (0–16) 7 (0–21) 2 (0–10) 1 (0–9)
Site of initial tertiary care 129
 Columbia 91% 88% 82% 84%
 Other 9% 12% 18% 16%
Timing of oxygen initiation 129
 Before tertiary care 55% 56% 61% 68%
 After tertiary care 33% 31% 30% 29%
 Not initiated 12% 13% 9% 3%
Therapies 129
 Prednisone 42% 38% 24% 33%
 Azathioprine 9% 13% 6% 3%
N-Acetylcysteine 30% 38% 30% 29%
 Other 3% 3% 3% 6%
Comorbidities 129
 Coronary artery disease 15% 19% 18% 26%
 Diabetes mellitus 18% 13% 12% 39%
 History of malignancy 15% 19% 15% 10%
 Gastroesophageal reflux 21% 28% 27% 65%
Health insurance 129
 Private 76% 75% 61% 58%
 Medicaid 6% 3% 9% 10%
 Medicare 45% 56% 45% 61%
Educational attainment 129
 Less than high school 6% 13% 12% 6%
 Completed high school 39% 41% 39% 36%
 Associate's degree 9% 9% 12% 13%
 Bachelor's degree or higher 45% 38% 36% 45%

Definition of abbreviations: DlCO = diffusing capacity for carbon monoxide; NYHA = New York Heart Association.

Data represent means (standard deviation), medians (interquartile range), and percentages.

All participants had health insurance.

*

One participant with a delay over 4 years was a current smoker. Pack-year data are shown for former/current smokers only (n = 80).

The time from evaluation at a tertiary care center to enrollment in the study was the entry time into the cohort in time-to-event analyses.

Other medications: pirfenidone (n = 3), cyclophosphamide (n = 1), IFN-γ (n = 1).